Stock Analiz

Biodesix Inc. BDSX

Medical Specialities · IPO 2020 · data as of November 13, 2026

$9.88Market cap $110M
Open the interactive analysis →

Biodesix Inc. (BDSX) is a healthcare company listed in the US with a market value of about $110M. In the twelve months to September 30, 2026 it had revenue of $105M and net income of -$27M, a net margin of -25.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 14% a year, a 5-year average ROIC of -56%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.

About Biodesix

Biodesix is listed in the US and classified in medical specialities, IPO year 2020. Revenue went from $25M in 2019 to $88M in 2025, growth of about 23.8% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 259% over three years (dilution for shareholders). It spends 14% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.0
P/B12.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.4%
Shareholder yield0.0%
Intrinsic value vs. price−83%

Growth and quality

Revenue growth (1 yr)24.1%
Revenue growth (5 yrs, per year)14.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-91.3%
ROIC (5-yr avg.)-56.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$105M$88M$71M$49M$38M$55M$46M$25M
Net income-$27M-$35M-$43M-$52M-$65M-$43M-$65M-$31M
Free cash flow-$19M-$24M-$52M-$46M-$48M-$30M-$23M-$23M
EPS (diluted)$-2.70$-4.67$-6.64$-12.83$-31.06$-31.67$-129.87$-2544.70
Net margin-25.7%-39.9%-60.2%-106.2%-171.3%-79.2%-143.7%-125.2%
ROIC—-30.2%-31.5%-46.6%-69.5%-103.3%-26.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Biodesix stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Biodesix pay a dividend?

Not currently.

Is Biodesix a good stock to buy?

We do not give buy or sell advice. Biodesix scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.